Oligoarginine-linked polymers as a new class of penetration enhancers

Journal of Controlled Release

Volumn 148, Issue 2, 2010, Pages 187-196

  Sakuma, Shinji ^a   Suita, Masaya ^a   Masaoka, Yoshie ^a   Kataoka, Makoto ^a   Nakajima, Noriko ^b   Shinkai, Norihiro ^b   Yamauchi, Hitoshi ^c   Hiwatari, Ken ichiro ^c   Tachikawa, Hiroyuki ^c   Kimura, Ryoji ^c   Yamashita, Shinji ^a  

^a SETSUNAN UNIVERSITY   (Japan)

^b Nipro Patch Co Ltd   (Japan)

^c ADEKA CORPORATION   (Japan)

Author keywords

Cell penetrating peptides; Oligoarginines; Penetration enhancer; Poly(N vinylacetamide co acrylic acid)

Indexed keywords

ACRYLIC ACIDS; ARGININE RESIDUE; BIOACTIVE MOLECULES; BLOOD GLUCOSE CONCENTRATION; CELL-PENETRATING PEPTIDE; CELLULAR UPTAKE; FLUORESCEIN ISOTHIOCYANATE DEXTRANS; GRAFTING DEGREE; HYPOGLYCEMIC EFFECT; IN-VITRO; MEMBRANE-PERMEABLE; N-VINYLACETAMIDE; NASAL ADMINISTRATION; NOVEL POLYMERS; OLIGOARGININE; OLIGOARGININES; OPTICAL ISOMERS; PENETRATION ENHANCERS; POLYMER BACKBONES;

AMINO ACIDS; BLOOD; CARBOXYLIC ACIDS; CELL MEMBRANES; CYTOLOGY; FUNCTIONAL GROUPS; FUNCTIONAL POLYMERS; GLUCOSE; GRAFTING (CHEMICAL); INSULIN; ORGANIC ACIDS; ORGANIC POLYMERS; PEPTIDES;

POLYMERS;

ACRYLIC ACID DERIVATIVE; ARGININE DERIVATIVE; GLUCOSE; INSULIN; OLIGOARGININE; POLY N VINYLACETAMIDE CO ACRYLIC ACID; POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE; CHEMICAL REACTION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; FEMALE; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETAMIDES; ACRYLATES; ADMINISTRATION, INTRANASAL; ANIMALS; BLOOD GLUCOSE; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MICE; NASAL MUCOSA; OLIGOPEPTIDES; PEPTIDES; POLYVINYLS; TIME FACTORS; VENOMS;

EID: 78649315934     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.08.022     Document Type: Article

References (33)

1. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P. Experimental and computational approaches to estimate solubility and permeability in drug delivery and development setting. Adv. Drug Deliv. Rev. 2001, 46:3-26.
2. Sakuma S., Matsumoto T., Yamashita S., Wang Y., Lu Z.-R. Conjugation of poorly absorptive drugs with mucoadhesive polymers for the improvement of oral absorption of drugs. J. Control. Release 2007, 123:195-202.
3. Amidon G.L., Lennernäs H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12:413-420.
4. Tavelin S., Hashimoto K., Malkinson J., Lazorova L., Toth I., Artursson P. A new principle for tight junction modulation based on occluding peptides. Mol. Pharmacol. 2005, 64(6):1530-1540.
5. Muranishi S. Absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 1990, 7:1-34.
6. Sakuma S., Hayashi M., Akashi M. Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv. Drug Deliv. Rev. 2001, 47:21-37.
7. van der Merwe S.M., Verhoef J.C., Verheijden J.H., Kotze A.F., Junginger H.E. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur. J. Pharm. Biopharm. 2004, 58(2):225-235.
8. Morishita M., Goto T., Nakamura K., Lowman A.M., Takayama K., Peppas N.A. Novel oral insulin delivery systems based on complexation polymer hydrogels: single and multiple administration studies in type 1 and 2 diabetic rats. J. Control. Release 2006, 110:587-594.
9. Uchiyama T., Kotani A., Tatsumi H., Kishida T., Okamoto A., Yamamoto A. Development of novel lipophilic derivatives of DADLE (Leucine enkephalin analogue): Intestinal permeability characteristics of DADLE derivatives in rats. Pharm. Res. 2000, 17(12):1461-1467.
10. Futaki S., Ohashi W., Suzuki T., Niwa M., Tanaka S., Ueda K., Harashima H., Sugiura Y. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjugate Chem. 2001, 12(6):1005-1011.
11. Futaki S. Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int. J. Pharm. 2002, 245(1-2):1-7.
12. Kogure K., Moriguchi R., Sasaki K., Ueno M., Futaki S., Harashima H. Development of a non-vial multifunctional envelope-type nano device by a novel lipid film hydration method. J. Control. Release 2004, 98(2):317-323.
13. Futaki S. Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv. Drug Deliv. Rev. 2005, 57(4):547-558.
14. Nakase I., Takeuchi T., Tanaka G., Futaki S. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv. Drug Deliv. Rev. 2008, 60(4-5):598-607.
15. Rothbard J.B., Jessop T.C., Lewis R.S., Murray B.A., Wender P.A. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J. Am. Chem. Soc. 2004, 126(31):9506-9507.
16. Ziegler A., Seelig J. Interaction of the protein transduction domain of HIV-1 TAT with heparin sulfate: binding mechanism and thermodynamic parameters. Biophys. J. 2004, 86(1 Pt 1):254-263.
17. Goncalves E., Kitas E., Seelig J. Binding of oligoarginine to membrane lipids and heparin sulfate: structural and thermodynamic characterization of a cell-penetrating peptide. Biochemistry 2005, 44(7):2692-2702.
18. Fuchs S.M., Raines R.T. Pathway for polyarginine entry into mammalian cells. Biochemistry 2004, 43(9):2438-2444.
19. Jones A.T. Macropinocytosis: searching for an endocytic identity and a role in the uptake of cell penetrating peptides. J. Cell. Mol. Med. 2007, 11(4):670-684.
20. Conner S.D., Schmid S.L. Regulated portals of entry into the cell. Nature 2003, 422(6927):37-44.
21. Morishita M., Kamei N., Ehara J., Isowa K., Takayama K. A novel approach using functional peptides for efficient intestinal absorption of insulin. J. Control. Release 2007, 118(2):177-184.
22. Kamei N., Morishita M., Ehara J., Takayama K. Permeation characteristics of oligoarginine through intestinal epithelium and its usefulness for intestinal peptide drug delivery. J. Control. Release 2008, 131(2):94-99.
23. Kamei N., Morishita M., Wada Y., Ida N., Nishio R., Takayama K. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J. Control. Release 2008, 132(1):21-25.
24. Kamei N., Morishita M., Takayama K. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J. Control. Release 2009, 136(3):179-186.
25. Khafagy E.S., Morishita M., Isowa K., Imai J., Takayama K. Effect of cell-penetrating peptides on the nasal absorption of insulin. J. Control. Release 2009, 133(2):103-108.
26. Chow K.T., Chan L.W., Heng P.W.S. Formulation of hydrophilic non-aqueous gel: drug stability in different solvents and rheological behavior of gel matrices. Pharm. Res. 2008, 25(1):207-217.
27. Wender P.A., Mitchell D.J., Pattabiraman K., Pelkey E.T., Steinman L., Rothbard J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl Acad. Sci. USA 2000, 97:13003-13008.
28. Hiwatari K., Sakuma S., Iwata K., Masaoka Y., Kataoka M., Tachikawa H., Shoji Y., Yamashita S. Poly(N-vinylacetamide) chains enhance lectin-induced biorecognition through the reduction of nonspecific interactions with non-targets. Eur. J. Pharm. Biopharm. 2008, 70(2):453-461.
29. Sakuma S., Yano T., Masaoka Y., Kataoka M., Hiwatari K., Tachikawa H., Shoji Y., Kimura R., Ma H., Yang Z., Tang L., Hoffman R.M., Yamashita S. In vitro/in vivo biorecognition of lectin-immobilized fluorescent nanospheres for human colorectal cancer cells. J. Control. Release 2009, 134(1):2-10.
30. Sakuma S., Yano T., Masaoka Y., Kataoka M., Hiwatari K., Tachikawa H., Shoji Y., Kimura R., Ma H., Yang Z., Tang L., Hoffman R.M., Yamashita S. Detection of early colorectal cancer imaged with peanut agglutinin-immobilized fluorescent nanospheres having surface poly(N-vinylacetamide) chains. Eur. J. Pharm. Biopharm. 2010, 74(3):451-460.
31. Gribble F.M., Williams L., Simpson A.K., Reimann F. A novel glucose-sensing mechanism contributing to glucagons-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003, 52(5):1147-1154.
32. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., Wintle M.E., Maggs D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3years. Curr. Med. Res. Opin. 2008, 24(1):275-286.
33. Gedulin B.R., Smith P.A., Jodka C.M., Bhavsar S., Nielsen L.L., Parkes D.G., Young A.A. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int. J. Pharm. 2008, 356(1-2):231-238.